What are our pharmacotherapeutic options for MERS-CoV? (Q45006404)

8 December 2017

0 references

What are our pharmacotherapeutic options for MERS-CoV? (English)

1 reference

Middle East respiratory syndrome coronavirus

8 December 2017

main subject

0 references

2

Ziad A Memish

1 reference

8 December 2017

1

Jaffar A Al-Tawfiq

1 reference

8 December 2017

language of work or name

English

0 references

publication date

3 March 2014

1 reference

Expert Review of Clinical Pharmacology

8 December 2017

published in

1 reference

8 December 2017

volume

7

1 reference

8 December 2017

issue

3

1 reference

8 December 2017

page(s)

235-238

1 reference

Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy

8 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

SARS: systematic review of treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

Identification of severe acute respiratory syndrome in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

A cluster of cases of severe acute respiratory syndrome in Hong Kong.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

Efficient replication of the novel human betacoronavirus EMC on primary human epithelium highlights its zoonotic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.890515

10.1586/17512433.2014.890515

21 January 2018

Identifiers

DOI

1 reference

8 December 2017

1 reference